Denise A. Yardley

26.5k total citations · 8 hit papers
279 papers, 12.8k citations indexed

About

Denise A. Yardley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Denise A. Yardley has authored 279 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 244 papers in Oncology, 148 papers in Pulmonary and Respiratory Medicine and 87 papers in Cancer Research. Recurrent topics in Denise A. Yardley's work include Cancer Treatment and Pharmacology (154 papers), HER2/EGFR in Cancer Research (117 papers) and Advanced Breast Cancer Therapies (113 papers). Denise A. Yardley is often cited by papers focused on Cancer Treatment and Pharmacology (154 papers), HER2/EGFR in Cancer Research (117 papers) and Advanced Breast Cancer Therapies (113 papers). Denise A. Yardley collaborates with scholars based in United States, United Kingdom and France. Denise A. Yardley's co-authors include Hope S. Rugo, Howard A. Burris, John D. Hainsworth, Adam Brufsky, F. Anthony Greco, Véronique Dièras, Joyce O’Shaughnessy, Alison Stopeck, Eric P. Winer and Ada Braun and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Denise A. Yardley

275 papers receiving 12.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

2010 1.1k citations Alison Stopeck, Allan Lipton et al. Journal of Clinical Oncology profile →
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

2017 918 citations Denise A. Yardley et al. profile →
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

2011 766 citations Véronique Dièras, Adam Brufsky et al. Journal of Clinical Oncology profile →
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

2017 490 citations Maura N. Dickler, Sara M. Tolaney et al. Clinical Cancer Research profile →
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

2015 458 citations Sara M. Tolaney, Chau T. Dang et al. profile →
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

2012 420 citations Allan Lipton, Alison Stopeck et al. profile →
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013 383 citations Denise A. Yardley, Howard A. Burris et al. profile →
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

2018 348 citations Tiffany A. Traina, Denise A. Yardley et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Denise A. Yardley

Since Specialization

Citations

This map shows the geographic impact of Denise A. Yardley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise A. Yardley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise A. Yardley more than expected).

Fields of papers citing papers by Denise A. Yardley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denise A. Yardley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise A. Yardley. The network helps show where Denise A. Yardley may publish in the future.

Co-authorship network of co-authors of Denise A. Yardley

This figure shows the co-authorship network connecting the top 25 collaborators of Denise A. Yardley. A scholar is included among the top collaborators of Denise A. Yardley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denise A. Yardley. Denise A. Yardley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	240P Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE 2024 ·Annals of Oncology ·Michael Untch, Denise A. Yardley, S-A Im, (unknown), L. Hart, John Crown, Gilles Freyer, C. Zamagni, Isabel Blancas, (unknown), Meng Gao, Krutika Amin, Hai Hu, (unknown)	1
2	Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 2023 ·Clinical Cancer Research ·Aleix Prat, Nadia Solovieff, Fabrice André, Joyce O’Shaughnessy, David Cameron, Wolfgang Janni, Gabe S. Sonke, Yoon Sim Yap, Denise A. Yardley, Ann H. Partridge, (unknown), Juan Pablo Zarate, Agnes Lteif, Fei Su, Lisa A. Carey	8
3	Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT) 2022 ·npj Breast Cancer ·Tal Sella, Yue Zheng, Nabihah Tayob, Kathryn J. Ruddy, Rachel A. Freedman, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Michelle K. DeMeo, Harold J. Burstein, Eric P. Winer, Antonio C. Wolff, Ian E. Krop, Ann H. Partridge, Sara M. Tolaney	5
4	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer 2021 ·British Journal of Cancer ·Howard A. Burris, Arlene Chan, Aditya Bardia, J. Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debu Tripathy, Seock‐Ah Im, Stephen Chia, Francisco J. Esteva, Lowell L. Hart, Juan Pablo Zarate, Antonia Ridolfi, Karen Rodriguez Lorenc, Denise A. Yardley	52
5	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer 2020 ·Clinical Cancer Research ·Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, Pierfranco Conté, Véronique Dièras, Nancy U. Lin, (unknown), Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders	144
6	Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1 2020 ·Breast Cancer Research and Treatment ·Hope S. Rugo, Véronique Dièras, Javier Cortés, Debra A. Patt, Hans Wildiers, Joyce O’Shaughnessy, Esther Zamora, Denise A. Yardley, Gebra Cuyún Carter, Kristin M. Sheffield, Li Li, Valérie André, (unknown), Martin Frenzel, (unknown), Maura N. Dickler, Sara M. Tolaney	3
7	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs 2019 ·Clinical Cancer Research ·Melody Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Vincent Antao, Haocheng Li, Laura Chu, Mohammad Jahanzeb	23
8	A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 2019 ·Clinical Breast Cancer ·Denise A. Yardley, William H. Liggett, Mark Mainwaring, Aurelio Castrellon, L. Johnetta Blakely, Brian Hemphill, Bertrand Anz, Robyn R. Young, Mythili Shastry, Laura M. DeBusk, John D. Hainsworth, Howard A. Burris	6
9	MONALEESA Clinical Program: A Review of Ribociclib use in Different Clinical Settings 2019 ·Future Oncology ·Denise A. Yardley	23
10	Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study 2018 ·Clinical Breast Cancer ·Denise A. Yardley, Lowell L. Hart, Patrick J. Ward, (unknown), Mythili Shastry, (unknown), Laura M. DeBusk, John D. Hainsworth	12
11	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs 2018 ·Clinical Cancer Research ·Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Laura Chu, Haocheng Li, Vincent Antao, Melody Cobleigh	63
12	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation 2018 ·Breast Cancer Research and Treatment ·Joyce O’Shaughnessy, Angela DeMichele, X. Cynthia, Paul Richards, Denise A. Yardley, Gail S. Wright, Kevin Kalinsky, Ronald G. Steis, Sami Diab, Gerard T. Kennealey, Ryan Geschwindt, Wei Jiang, Hope S. Rugo	35
13	A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer 2017 ·Clinical Cancer Research ·Lee S. Schwartzberg, Denise A. Yardley, Anthony Elias, Manish R. Patel, Patricia LoRusso, Howard A. Burris, Ayca Gucalp, Amy Peterson, Martha Blaney, Joyce Steinberg, Jacqueline A. Gibbons, Tiffany A. Traina	42
14	Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial 2016 ·Clinical Breast Cancer ·Denise A. Yardley, Natalie R. Dickson, (unknown), (unknown), Roger Inhorn, Patrick Murphy, John D. Hainsworth	11
15	Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy 2015 ·Clinical Cancer Research ·William J. Gradishar, Denise A. Yardley, Rachel M. Layman, Joseph A. Sparano, Ellen Chuang, Donald W. Northfelt, Gary N. Schwartz, Hagop Youssoufian, Shande Tang, Ruslan D. Novosiadly, Amélie Forest, Tuan S. Nguyen, Jan Cosaert, Dmitri Grebennik, Paul Haluska	54
16	EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer 2015 ·Journal of Clinical Oncology ·Denise A. Yardley, Robert Weaver, Michelle Melisko, Mansoor N. Saleh, Francis P. Arena, Andres Forero, Tessa Cigler, Alison Stopeck, Dennis L. Citrin, Ira A. Oliff, (unknown), Randa Loutfi, Agustin A. García, Scott Cruickshank, Elizabeth Crowley, Jennifer Green, Thomas Hawthorne, Michael Yellin, Thomas A. Davis, Linda T. Vahdat	145
17	Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer 2014 ·Cancer ·Peter A. Kaufman, Kenneth J. Bloom, Howard A. Burris, Julie R. Gralow, Musa Mayer, Mark D. Pegram, Hope S. Rugo, Sandra M. Swain, Denise A. Yardley, (unknown), Deepa Lalla, Bongin Yoo, Melissa Brammer, Charles L. Vogel	47
18	Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study 2012 ·Breast Cancer Research and Treatment ·Peter A. Kaufman, Adam Brufsky, Musa Mayer, Hope S. Rugo, Debu Tripathy, Marianne Ulcickas Yood, Shibao Feng, Lisa I. Wang, Cheng S. Quah, Denise A. Yardley	45
19	Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER 2011 ·Clinical Cancer Research ·Adam Brufsky, Musa Mayer, Hope S. Rugo, Peter A. Kaufman, Elizabeth Tan-Chiu, Debu Tripathy, Iulia Cristina Tudor, Lisa I. Wang, Melissa Brammer, Mona Shing, Marianne Ulcickas Yood, Denise A. Yardley	283
20	Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study breakdown → 2010 ·Journal of Clinical Oncology ·Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun	1102

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact